Amarantus Bioscience Holdings Inc (AMBS)

[MagicCap]

Close above $0.069 for new closing high since October.

I always look at closing prices instead of the intraday noise.

Again, $14 Million market cap for a company with patent protection on a drug that has had much better results than GDNF which was owned by a company bought out for $250 Million and a drug that the co-founder of Amgen said the following about:

"I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug."

Do the math. $14 Million vs $250 Million. We will see a $100 Million market cap soon.

Dr. Rubinfeld is presenting on 1/8/13. Do you think the data is going to be good?